ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
49 announcements with these filters
Sudarshan Pharma Industries promoter Mr. Hemal Vasantrai Mehta pledged 20,00,000 shares on June 3, 2026. This creation of encumbrance increases promoter leverage and overall risk profile.
Sudarshan Pharma re-submitted its audited FY26 financial results to address BSE discrepancies. The filing ensures regulatory compliance and provides corrected standalone and consolidated performance data.
Sudarshan Pharma Industries submitted its Annual Secretarial Compliance Report for FY2026. The report by a practicing company secretary confirms overall regulatory compliance with no material penalties.
Sudarshan Pharma Industries issued a postal ballot notice for shareholder voting on migration to the main board. Remote e-voting ends on June 24, 2026.
Sudarshan Pharma Industries revised its FCCB conversion rate to Rs.96.8441 per USD following updated RBI rates. The USD 20 million issue reflects a Rs.193.69 Crore value.
Sudarshan Pharma's board approved migrating its equity shares from BSE SME to the Main Board. It also plans to list on the NSE Main Board.
Sudarshan Pharma allotted ₹96 Crore worth of FCCBs due 2029. This capital infusion strengthens liquidity and provides a route for future equity conversion.
Sudarshan Pharma pre-poned its board meeting to May 21, 2026, to consider migrating from the BSE SME platform to the main boards of BSE and NSE.
Sudarshan Pharma Industries scheduled a board meeting for May 22, 2026. Directors will consider migrating equity shares from BSE SME to the Main Board.
Sudarshan Pharma approved raising up to ₹191.86 Crore through Foreign Currency Convertible Bonds. This fund-raise strengthens the company's capital base for future growth and operations.
Sudarshan Pharma scheduled a board meeting for May 15, 2026, to consider issuing Foreign Currency Convertible Bonds. The proposal remains subject to regulatory and statutory approvals.
Mr. Sachin Mehta resigned as Chief Financial Officer effective May 1, 2026. He will continue serving as the company's Joint Managing Director.
Mr. Sachin Mehta has resigned as Chief Financial Officer of Sudarshan Pharma Industries Ltd, effective May 1, 2026. He will continue to serve the company in his capacity as Joint Managing Director. This transition represents a focused leadership adjustment within the organization's senior management structure.
Sudarshan Pharma Industries Ltd appointed Mr. Sanat Bhat (Independent Director), Dr. Vinay Pandey (Non-Executive Director), and Mr. Sharad Govindrao Kathawate (CFO) effective May 1, 2026. These leadership changes bring expertise in finance, infrastructure, and geotechnical engineering to the board and management team.
Sudarshan Pharma Industries Ltd reported revenue from operations of ₹220.9 Cr (+36.7% YoY) and net profit of ₹11.4 Cr (+54.1% YoY) for Q4 FY26.
Sudarshan Pharma Industries Ltd reported consolidated total income of ₹711.77 Crore for the financial year ended March 31, 2026. Consolidated net profit reached ₹23.30 Crore, up from ₹14.97 Crore in the previous year. The company successfully transitioned to Ind AS reporting during the period, reflecting strong operational growth and expanded financial transparency.
Sudarshan Pharma Industries Ltd has scheduled a Board Meeting on April 30, 2026. The board will consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The company's trading window remains closed for 48 hours post-declaration.
Sudarshan Pharma Industries Ltd reported net profit of ₹4.1 Cr (+41.4% YoY) for Q3 FY26.
Sudarshan Pharma Industries Ltd submitted certificates under Regulation 74(5) of SEBI Regulations for the quarter ended March 31, 2026. The certificates from KFin Technologies confirm compliance regarding the dematerialization and rematerialization of securities.